trending Market Intelligence /marketintelligence/en/news-insights/trending/6EhX_Z685tfMUwZQBOkssQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Biofrontera acquires dermatology company Cutanea for $1

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Biofrontera acquires dermatology company Cutanea for $1

Biofrontera AG will acquire U.S.-based dermatology company Cutanea Life Sciences Inc., which markets an acne treatment and other products, for $1.

Germany's Biofrontera will acquire the company through a subsidiary from Japan's Maruho Co. Ltd., which holds a 20% stake in Biofrontera, according to a March 25 press release.

Besides the acne treatment Aktipak, Cutanea in November 2018 launched Xepi, a treatment for a bacterial skin infection called impetigo.

Maruho plans to provide up to $7.3 million in startup funds for the development of Biofrontera's drug candidates through the transaction. Profits from Aktipak and Xepi will later be split between Maruho and Biofrontera.